Duopharma Biotech BhdXKLS:7148 82 Net Margin % is 12.39% as of Mar. 2026, which is 31% above its 10-year median of 9.47. GuruFocus rates XKLS:7148 with a GF Score™ of 82/100 and a GF Value™ of RM1.52 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Duopharma Biotech Bhd ranks better than 64.64% on this metric.
The historical rank and industry rank for Duopharma Biotech Bhd's Net Margin % or its related term are showing as below:
XKLS:7148'
s Net Margin % Range Over the Past 10 Years
Min: 7.47 Med: 9.47 Max: 10.28
Current: 10.09
XKLS:7148's Net Margin % is ranked better than 64.64% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs XKLS:7148: 10.09
Duopharma Biotech Bhd (XKLS:7148) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Duopharma Biotech Bhd Net Margin % Related Terms
Duopharma Biotech Bhd Net Margin % Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Net Margin % distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a Net Margin % of 12.39% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Duopharma Biotech Bhd and its competitors. This is 31% above median its historical median of 9.47. Over the past decade, Duopharma Biotech Bhd's Net Margin % has ranged from 7.47 to 10.28. According to the industry distribution chart, Duopharma Biotech Bhd ranks #338 out of 956 companies in the Drug Manufacturers industry, placing it in the top 35.4%.
Is Duopharma Biotech Bhd's Net Margin % too high?
Duopharma Biotech Bhd's current Net Margin % of 12.39% is 31% above median its 10-year median of 9.47. Over the past 10 years, this metric has ranged from a low of 7.47 to a high of 10.28. The Drug Manufacturers industry median Net Margin % is 5.56. Duopharma Biotech Bhd's value of 12.39% is 122.8% above this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #338 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #338 out of 956 companies for Net Margin %. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median Net Margin % is 5.56. Duopharma Biotech Bhd's value of 12.39% is 122.8% above this benchmark. Historically, Duopharma Biotech Bhd's own Net Margin % has ranged from 7.47 to 10.28 over the past decade. While the company's 10-year median is 9.47 vs. the industry median of 5.56, Duopharma Biotech Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current Net Margin % of 12.39% is 122.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current Net Margin % is 12.39%, which is 31% above median its own 10-year median of 9.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.52, compared to a current price of RM1.20 — trading 21.1% below its estimated fair value. The current Net Margin % is 12.39%, which is 31% above median its 10-year median of 9.47 and 122.8% above the Drug Manufacturers industry median of 5.56. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Net Margin % is 12.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.20 is trading 21.1% below its estimated GF Value™ of RM1.52.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Net Margin %: 12.39% (31% above median its 10-year median of 9.47)
GF Value™: RM1.52 vs. price of RM1.20 (21.1% below fair value)
Industry Position: 122.8% above the Drug Manufacturers median (#338 of 956)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score
Get the complete analysis for XKLS:7148
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
